Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)

The Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies grant, which includes an optional clinical trial (R01), is intended to support cooperation in research efforts. These projects focus on the long-lasting negative side effects of cancer treatments, which often develop into chronic health problems or delayed effects after treatment.

The funding supports three types of research; basic, translational, and clinical. All are intended to understand the mechanisms behind these adverse side effects, provide a detailed clinical description of them, and use the understanding of their mechanisms to develop therapeutic strategies that can prevent or significantly reduce the long-term side effects.

The research projects should concentrate on mechanistic studies with translational endpoints. They should include longitudinal clinical data to identify and validate clinical endpoints, such as biomarkers, imaging, patient-reported outcomes, or combined elements. These will be used in future clinical trials to evaluate the effectiveness of interventions designed to prevent or lessen these specific adverse effects.